1. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- Author
-
Lopes, Renato D, Heizer, Gretchen, Aronson, Ronald, Vora, Amit N, Massaro, Tyler, Mehran, Roxana, Goodman, Shaun G, Windecker, Stephan, Darius, Harald, Li, Jia, Averkov, Oleg, Bahit, M Cecilia, Berwanger, Otavio, Budaj, Andrzej, Hijazi, Ziad, Parkhomenko, Alexander, Sinnaeve, Peter, Storey, Robert F, Thiele, Holger, Vinereanu, Dragos, Granger, Christopher B, and Alexander, John H
- Subjects
610 Medicine & health - Abstract
BACKGROUND Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P
- Published
- 2019
- Full Text
- View/download PDF